Savara Inc (SVRA) Given Average Recommendation of “Buy” by Analysts

Savara Inc (NASDAQ:SVRA) has been given a consensus recommendation of “Buy” by the eight ratings firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $21.17.

SVRA has been the subject of a number of research reports. LADENBURG THALM/SH SH reiterated a “buy” rating and set a $21.00 price objective on shares of Savara in a report on Monday, April 1st. Canaccord Genuity set a $22.00 price target on Savara and gave the company a “buy” rating in a research report on Monday, March 25th. Zacks Investment Research raised Savara from a “hold” rating to a “buy” rating and set a $10.00 price target for the company in a research report on Thursday, April 11th. BidaskClub raised Savara from a “hold” rating to a “buy” rating in a research report on Friday, April 5th. Finally, ValuEngine raised Savara from a “sell” rating to a “hold” rating in a research report on Monday, April 1st.

Shares of NASDAQ:SVRA traded up $0.31 during mid-day trading on Tuesday, reaching $9.32. 95,906 shares of the stock were exchanged, compared to its average volume of 184,692. The company has a debt-to-equity ratio of 0.23, a quick ratio of 15.63 and a current ratio of 15.63. The company has a market cap of $333.94 million, a PE ratio of -7.22 and a beta of 0.86. Savara has a one year low of $6.21 and a one year high of $14.06.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Wednesday, March 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.08. On average, research analysts predict that Savara will post -1.55 earnings per share for the current fiscal year.

In related news, COO Jaakko Taneli Jouhikainen sold 7,815 shares of the stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $9.00, for a total transaction of $70,335.00. Following the completion of the transaction, the chief operating officer now directly owns 184,754 shares of the company’s stock, valued at $1,662,786. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO David L. Lowrance sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $9.02, for a total value of $67,650.00. Following the completion of the sale, the chief financial officer now directly owns 2,446 shares of the company’s stock, valued at $22,062.92. The disclosure for this sale can be found here. Insiders have sold 42,761 shares of company stock valued at $385,749 over the last three months. Insiders own 6.10% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Simplex Trading LLC lifted its position in shares of Savara by 246.1% in the fourth quarter. Simplex Trading LLC now owns 4,997 shares of the company’s stock valued at $37,000 after buying an additional 3,553 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Savara during the fourth quarter worth approximately $82,000. Jane Street Group LLC bought a new position in shares of Savara during the fourth quarter worth approximately $93,000. D. E. Shaw & Co. Inc. bought a new position in shares of Savara during the fourth quarter worth approximately $111,000. Finally, Alliancebernstein L.P. bought a new position in shares of Savara during the third quarter worth approximately $118,000. 48.42% of the stock is owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Featured Story: Stop Order Uses For Individual Investors

Analyst Recommendations for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.